Ovary, Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome

Primary Objectives:

To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function.
To assess the safety and tolerability of lademirsen (SAR339375) in participants with Alport syndrome.

Contact Information

For more information about this study, including how to volunteer, contact Lisa Baker

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Principal Investigator